Get the Stockscreener App
4.01
0.12%
0.005
Pre-market:
3.88
-0.13
-3.24%
Eupraxia Pharmaceuticals Inc stock is traded at $4.01, with a volume of 88,450.
It is up +0.12% in the last 24 hours and up +37.09% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
See More
Previous Close:
$4.005
Open:
$4.17
24h Volume:
88,450
Relative Volume:
5.30
Market Cap:
$143.04M
Revenue:
-
Net Income/Loss:
$-25.50M
P/E Ratio:
-5.2078
EPS:
-0.77
Net Cash Flow:
$-30.10M
1W Performance:
+0.50%
1M Performance:
+37.09%
6M Performance:
+22.07%
1Y Performance:
+36.39%
1-Day Range:
$3.9176
$4.4299
1-Week Range:
$3.86
$4.4299
52-Week Range:
$2.20
$4.48
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
4.01 | 143.04M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
(EPRX.WT.A) Strategic Equity Report - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Inc. - MENAFN.com
Stocks In Play: Eupraxia Pharmaceuticals Inc. By Baystreet.ca - Investing.com Canada
Aptose Biosciences Inc. - Baystreet.ca
Eupraxia Pharma Reports Positive 9-month Data From RESOLVE Phase 1b/2a Study - Nasdaq
Eupraxia Pharmaceuticals Reports Positive Nine-Month Outcomes in EoE Trial - TipRanks
When the Price of (EPRX) Talks, People Listen (EPRX:CA) - news.stocktradersdaily.com
Breakthrough: New EoE Drug Shows Unprecedented 9-Month DurationCould Transform Treatment Landscape - Stock Titan
(EPRX) Advanced Equity Analysis (EPRX:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Proactive Strategies (EPRX.WT.A:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Dynamic Trading Report - news.stocktradersdaily.com
How the (EPRX) price action is used to our Advantage (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals to Showcase Clinical Advances at April and May Conferences - MSN
Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May - The Manila Times
Eupraxia Pharmaceuticals Inc. to Present at Multiple Upcoming Investor and Scientific Conferences in April and May 2025 - Nasdaq
(EPRX) Trading Signals (EPRX:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Optimized Trading Opportunities - news.stocktradersdaily.com
(EPRX) Optimized Trading Opportunities (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - ADVFN
Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 - ADVFN
Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis - ADVFN
(EPRX.WT.A) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, 'Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed', on November 15, 2024 - ADVFN
(EPRX) Investment Performance Report (EPRX:CA) - news.stocktradersdaily.com
TSX Penny Stock Highlights Calfrac Well Services And Two More Compelling Picks - simplywall.st
Closing Bell: Eupraxia Pharmaceuticals Inc WT up on Wednesday (EPRX-WT) - The Globe and Mail
Long Term Trading Analysis for (EPRX.WT.A) - news.stocktradersdaily.com
(EPRX) Technical Pivots with Risk Controls (EPRX:CA) - news.stocktradersdaily.com
When (EPRX.WT.A) Moves Investors should Listen - news.stocktradersdaily.com
Raymond James Financial Inc. Makes New $37,000 Investment in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) - Defense World
(EPRX) Proactive Strategies (EPRX:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Investment Analysis and Advice - news.stocktradersdaily.com
(EPRX) Equity Trading Insights (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Stock Price Down 1% – Should You Sell? - Defense World
(EPRX) On The My Stocks Page (EPRX:CA) - news.stocktradersdaily.com
(EPRX) Strategic Investment Report (EPRX:CA) - news.stocktradersdaily.com
(EPRX) Stock Market Analysis (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (EPRX) Projected to Post Earnings on Monday - Defense World
When (EPRX) Moves Investors should Listen (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Reports Strong Q4 2024 Results and Operational Progress - MSN
Here's Why We're Watching Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation - Yahoo
Learn to Evaluate (EPRX) using the Charts (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals files report with SEC By Investing.com - Investing.com South Africa
Eupraxia Pharmaceuticals files report with SEC - Investing.com India
Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results -March 20, 2025 at 05:38 pm EDT - MarketScreener
(EPRX) Equity Market Report (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 1.7% – What’s Next? - The AM Reporter
How to Take Advantage of moves in (EPRX) (EPRX:CA) - Stock Traders Daily
(EPRX) Daily Stock Insights (EPRX:CA) - Stock Traders Daily
(EPRX) Stock Evaluation Report (EPRX:CA) - Stock Traders Daily
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):